Opdivo is still deriving a lot of sales from second-line NSCLC patients who did not get Keytruda in the first line. (About half of first-line NSCLC patents are getting Keytruda, a proportion that is steadily increasing.)
Opdivo also remains the leading I-O drug in melanoma and RCC.
Market Data 
Markets 
AI
